Key Highlights

‍

Study Focus

Initial experience reported by physicians of next-generation eCLIPs device for retreatment of wide-neck bifurcation aneurysm recurrences that were first treated with intrasaccular devices (WEB, Contour, or Artisse).

Data Source

‍Multicenter, prospectively maintained registry encompassing 21 patients treated between October 2022 and December 2024

Treatment Context

These patients had previously been treated using one of the three intrasaccular devices and experienced recurrence; the eCLIPs implant was used for retreatment

Technical Success and Deployment

eCLIPs was successfully deployed in all intended retreatment cases, demonstrating excellent technical feasibility

Aneurysm Characteristics

• Median recurrence size: 7.0mm (range: 2.1-10.3mm)
• Median aspect ratio: 0.87 (range: 0.50-2.24)
• Median dome-to-neck ratio: 1.16 (range: 0.53-1.69)

Follow-Up Outcomes

Among the 13 patients with follow-up data available (median of 11 months):

• 10 achieved complete occlusion (mRROC = 1)
• 3 had near-complete occlusion (mRROC = 2)
• No device-related safety events were reported during this period

Conclusion

The next-generation eCLIPs appears both safe and technically reliable for treating aneurysm recurrences after intrasaccular device failure. While the durability of treatment is promising, long-term prospective studies are encouraged to validate these early findings.

‍

Why This Matters

This study demonstrates that eCLIPs provides a safe and reliable option for managing challenging aneurysm recurrences where initial intrasaccular devices were insufficient. These results highlight the device’s versatility and reinforce its role in advancing patient care in complex neurovascular procedures. It underscores:

• A high technical success rate in deployment, even in challenging reccurent lesions.
• A potential therapeutic pathway where intrasaccular devices fall short.

‍

Read the full publication

‍